Swedish Orphan Biovitrum AB (Swedish Orphan Biovitrum AB) Operating Cash Flow per Share : $0.66 (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Swedish Orphan Biovitrum AB Operating Cash Flow per Share?

Swedish Orphan Biovitrum AB's operating cash flow per share for the three months ended in Mar. 2024 was $0.32. Swedish Orphan Biovitrum AB's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.66.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Swedish Orphan Biovitrum AB was -11.10% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -4.60% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 11.70% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 43.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Swedish Orphan Biovitrum AB's Operating Cash Flow per Share or its related term are showing as below:

SWOBY' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -91.8 Med: 24.75 Max: 113.2
Current: -4.6

During the past 13 years, Swedish Orphan Biovitrum AB's highest 3-Year average Operating Cash Flow per Share Growth Rate was 113.20% per year. The lowest was -91.80% per year. And the median was 24.75% per year.

SWOBY's 3-Year OCF Growth Rate is ranked worse than
65.51% of 806 companies
in the Drug Manufacturers industry
Industry Median: 6.9 vs SWOBY: -4.60

Swedish Orphan Biovitrum AB Operating Cash Flow per Share Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Operating Cash Flow per Share Chart

Swedish Orphan Biovitrum AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

0.63

0.95

0.97

0.71

0.67

Swedish Orphan Biovitrum AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Cash Flow per Share	Get a 7-Day Free Trial															0.30	0.05	0.15	0.15	0.32

Competitive Comparison of Swedish Orphan Biovitrum AB's Operating Cash Flow per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Swedish Orphan Biovitrum AB's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Price-to-Operating-Cash-Flow falls into.

Swedish Orphan Biovitrum AB Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Swedish Orphan Biovitrum AB's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	435.774	/	651.935
	=	0.67

Swedish Orphan Biovitrum AB's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )	=	Cash Flow from Operations (Q: Mar. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
	=	216.688	/	688.132
	=	0.31

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.66

Swedish Orphan Biovitrum AB Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Swedish Orphan Biovitrum AB (Swedish Orphan Biovitrum AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OTCPK:SWOBY) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

BIOVF:USA SOBI:Sweden SOBIs:UK 0MTD:UK B6E:Germany

Address

Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76

Website

https://www.sobi.com

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).